Centene Plans To Reaffirm 2024 Adjusted EPS Guidance Of Greater Than $6.80 (Est $6.83); Reiterate Shift Of 20 To 30 Cents Of Adjusted EPS From Q3 To Q4, With Q3 Adjusted EPS At $1.31 - $1.41 (Est $1.51) - Filing
Portfolio Pulse from Benzinga Newsdesk
Centene plans to reaffirm its 2024 adjusted EPS guidance of over $6.80, with a shift of 20 to 30 cents of EPS from Q3 to Q4. Q3 EPS is projected at $1.31-$1.41, below the estimated $1.51. The company is optimistic about its Medicare Advantage stars program.
September 10, 2024 | 10:17 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Centene plans to reaffirm its 2024 adjusted EPS guidance of over $6.80, with a shift of 20 to 30 cents of EPS from Q3 to Q4. Q3 EPS is projected at $1.31-$1.41, below the estimated $1.51. The company is optimistic about its Medicare Advantage stars program.
Centene's reaffirmation of its 2024 EPS guidance and the shift of EPS from Q3 to Q4 indicates a strategic financial adjustment. The Q3 EPS projection is below estimates, which might concern investors, but the overall annual guidance remains strong. The positive progress in the Medicare Advantage stars program is a favorable sign for future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100